
|Videos|August 18, 2014
Suzanne Fuqua Discusses the Y537 Hotspot in Breast Cancer
Author(s)Suzanne A. W. Fuqua, PhD
Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.
Advertisement
Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.
Fuqua says there is a fairly high frequency of this mutation in metastatic breast cancers. These mutations are estrogen independent, meaning that hormones are not needed to activate the receptor. The clinical assumption is that the mutation would confer resistance to an aromatase inhibitor, Fuqua says. However, there is no direct clinical evidence of this because the majority of patients that have been examined have undergone multiple rounds of hormonal therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
2
FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma
3
ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention
4
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
5




















































